U.S., Oct. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07221799) titled 'OER Glibenclamide for Neuropathic Pain in Multiple Sclerosis' on Oct. 17.
Brief Summary: This is an early phase safety evaluation of the use of oral extended release (OER) glibenclamide, which is otherwise known as glyburide, for use as a treatment for neurologic pain in people with multiple sclerosis. Patients will receive medication to assess safety and tolerability.
Study Start Date: Sept. 01, 2026
Study Type: INTERVENTIONAL
Condition:
Multiple Sclerosis
Neuropathic Pain
Intervention:
DRUG: glibenclamide
oral extended release pill
DRUG: Placebo
Placebo
Recruitment Status: NOT_YET_RECRUITING
Sponsor: University of Maryl...